ustekinumab-hmny (Starjemza) vs ustekinumab-srlf (Imuldosa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-12 p40 · full Psoriasis pipeline
ustekinumab-hmny (Starjemza)
Marketed by Bio-Thera Solutions and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
ustekinumab-srlf (Imuldosa)
Marketed by Accord BioPharma Inc. and partners
NCT04785326 · Phase 3 · completed
Randomized, double-blind and controlled against the reference product Stelara in 598 patients, with a sample size calculated for the primary measure and exceeded. The primary measure, percent improvement in psoriasis severity (PASI), showed equivalence at both prespecified time points: difference -0.35 points at week 8 and -0.30 at week 12, each confidence interval inside its margin.
Reported efficacy
• To Evaluate Efficacy of DMB-3115 in Comparison With Stelara (Week 8 (For EMA) and 12 (For FDA)): Percent change in PASI, DMB-3115 vs Stelara: week 8 (EMA) 77.50% vs 77.85%, LS mean difference -0.35 (95% CI -3.60 to 2.90, margin -15 to 15); week 12 (FDA) 87.59% vs 87.89%, difference -0.30 (90% CI -2.37 to 1.76, margin -10 to 10); equivalence shown at both (Tichy et al., JAAD Int 2025). (met)
Result source: NCT04785326
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ustekinumab-hmny (Starjemza) | ustekinumab-srlf (Imuldosa) |
|---|---|---|
| PASI 75 | —Not posted · NCT04728360 | —Not reported |
| PASI 90 | —Not posted · NCT04728360 | —Not reported |
| PASI 100 | —Not posted · NCT04728360 | —Not reported |
| sPGA 0/1 | —Not posted · NCT04728360 | —Not reported |
| DLQI, change | —Not posted · NCT04728360 | —Not reported |
PASI 75
- ustekinumab-hmny (Starjemza)
- —Not posted · NCT04728360
- ustekinumab-srlf (Imuldosa)
- —Not reported
PASI 90
- ustekinumab-hmny (Starjemza)
- —Not posted · NCT04728360
- ustekinumab-srlf (Imuldosa)
- —Not reported
PASI 100
- ustekinumab-hmny (Starjemza)
- —Not posted · NCT04728360
- ustekinumab-srlf (Imuldosa)
- —Not reported
sPGA 0/1
- ustekinumab-hmny (Starjemza)
- —Not posted · NCT04728360
- ustekinumab-srlf (Imuldosa)
- —Not reported
DLQI, change
- ustekinumab-hmny (Starjemza)
- —Not posted · NCT04728360
- ustekinumab-srlf (Imuldosa)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ustekinumab-hmny (Starjemza): no structured comparison results are available for Psoriasis.
ustekinumab-srlf (Imuldosa): registry results are on file for Psoriasis, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ustekinumab-hmny (Starjemza)'s landscape · ustekinumab-srlf (Imuldosa)'s landscape